The Efficiency of Intravitreal Bevacizumab for the Treatment (Primary) of Diabetic Macular Oedema - 03 Month Anatomic and Visual Acuity Response. In a Selected Population in the Northern Territory, Australia. A Hospital Based Study
JavaScript is disabled for your browser. Some features of this site may not work without it.
The Efficiency of Intravitreal Bevacizumab for the Treatment (Primary) of Diabetic Macular Oedema - 03 Month Anatomic and Visual Acuity Response. In a Selected Population in the Northern Territory, Australia. A Hospital Based Study